Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Last trade$73.67
Day change-$3.99 (-5.14%)
Day range$72.86 – $79.04
Volume156,832
Market cap$1.15B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.15B
Price / earnings
—
Price / book
-21.65×
Price / sales
—
EV / sales
—
EV / EBITDA
-9.47×
Profitability
Earnings per share
-$9.36
Return on assets
-89.6%
Return on equity
260.83%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-3.33×
Current ratio
5.07×
Quick ratio
5.07×
Cash ratio
4.75×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$131.9M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for INBX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$1.3M
$0
$100K
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$1.3M
$0
$100K
$0
Selling, general and administrative
$8.25M
$5.71M
$5.57M
$5.28M
$6.42M
$6.02M
$16.66M
$7.9M
Research and development
$23.9M
$25.22M
$25.35M
$28.54M
$22.27M
$36.88M
$33.37M
$38.89M
Total operating expenses
$32.15M
$30.93M
$30.92M
$33.81M
$28.69M
$42.9M
$50.03M
$46.8M
Operating income
-$32.15M
-$30.93M
-$30.92M
-$33.81M
-$27.39M
-$42.9M
-$49.93M
-$46.8M
Interest expense
-$5.69M
-$3.51M
-$3.19M
-$3.18M
-$3.14M
-$2.69M
$0
$0
Income before taxes
-$36.65M
-$33.44M
-$32.83M
-$35.26M
-$28.65M
-$43.31M
-$47.87M
-$43.86M
Income taxes
$3K
$0
$0
$0
$2K
$0
$0
$0
Net income
-$36.65M
-$33.44M
-$32.83M
-$35.26M
-$28.65M
-$43.31M
-$47.87M
-$43.86M
Net income attributable to common shareholders
-$36.65M
-$33.44M
-$32.83M
-$35.26M
-$28.65M
-$43.31M
-$47.87M
-$43.86M
EBITDA
-$31.63M
-$30.39M
-$30.36M
-$33.23M
-$26.73M
-$42.23M
-$49.24M
-$46.04M
Basic earnings per share
-$2.34
-$2.15
-$2.11
-$2.28
-$1.85
-$2.80
-$3.09
-$2.84
Diluted earnings per share
-$2.34
-$2.15
-$2.11
-$2.28
-$1.85
-$2.80
-$2.99
-$2.84
Recent news
Company coverage with links to the original publishers.
DelveInsight released a comprehensive report on the chondrosarcoma clinical trial pipeline, highlighting 5+ emerging therapies in development by key players. Notable drugs include Ozekibart (INBRX-109) which received FDA acceptance for filing with a PDUFA goal date of April 2027, Ivosidenib in Phase III trials, and RBT-102 in preclinical stages. The pipeline focuses on novel mechanisms including DR5 agonism and IDH1 inhibition to address this rare, high-unmet-need oncology market.
Inhibrx Biosciences reported Q1 2026 results with a net loss of $33.4 million ($2.15 per share), improved from $43.3 million in Q1 2025. The company raised $75 million in debt financing, bringing cash to $161.7 million. R&D expenses decreased to $25.2 million due to lower clinical trial costs. Key programs include INBRX-106 for head and neck cancer with Phase 2 PFS data expected in Q4 2026, and ozekibart (INBRX-109) for colorectal cancer and chondrosarcoma with a BLA submitted to the FDA.
Inhibrx Biosciences is in early-stage discussions with multiple major pharmaceutical companies regarding a potential joint spin-off of its cancer drug INBRX-106 and another oncology asset, with combined valuations potentially exceeding $9 billion. INBRX-106 is being tested as a standalone therapy and in combination with Merck's Keytruda. The stock surged 39.86% to $116.76 on the news.
U.S. stock markets hit record highs after September's inflation data showed a softer-than-expected 3% annual rate, boosting investor confidence in potential Federal Reserve interest rate cuts. Major indices like S&P 500 and Dow Jones reached new peaks, with technology stocks leading the rally.
Inhibrx Biosciences announced positive Phase 2 trial results for ozekibart in treating chondrosarcoma, demonstrating significant progression-free survival improvement and becoming the first experimental therapy to show such benefit in this cancer type.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.